(Q39888640)

15 September 2017

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. (English)

1 reference

15 September 2017

0 references

1 reference

1 reference

Christine Blasey Ford

2

object named as

Christine M Blasey

0 references

Joseph K. Belanoff

4

object named as

Joseph K Belanoff

0 references

author name string

Coleman Gross

1

1 reference

PubMed ID

20339369

15 September 2017

Robert L Roe

3

1 reference

15 September 2017

25 March 2010

1 reference

15 September 2017

1 reference

15 September 2017

18

1 reference

15 September 2017

12

1 reference

15 September 2017

2295-2300

1 reference

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine

15 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Weight change with atypical antipsychotics in the treatment of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Consensus development conference on antipsychotic drugs and obesity and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Off-label use of antipsychotic medications in the department of Veterans Affairs health care system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Pharmacological management of atypical antipsychotic-induced weight gain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

A meta-analysis of the efficacy of second-generation antipsychotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Atypical antipsychotic drugs and the risk of sudden cardiac death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Mifepristone treatment of olanzapine-induced weight gain in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effectiveness of second generation antipsychotics: a systematic review of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Methodological issues relating to the measurement of food, energy and nutrient intake in human laboratory-based studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Correlates of response to Olanzapine in a North Indian Schizophrenia sample.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2010.51

1 reference

release_ajvlr7ic7zdivn5rgr2bzmude4

15 September 2017

0 references

PubMed ID

20339369

1 reference

PubMed ID

20339369